West Visayas State University

COLLEGE OF NURSING
Luna St., La Paz, Iloilo City 5000
Iloilo, Philippines
* Trunkline: (063) (033) 320-0870 loc 1313 * Telefax No.: (033) 320-0879 Acc. No.:
* Website: www.wvsu.edu.ph * Email Address: con@wvsu.edu.ph
PHI-18939-2-QM

DRUG STUDY

Name of Patient: __D.L.___________________________ Attending Physician: _ Dr. D.D.S.__________________

Age: __57 years old_ Ward/Bed Number: _Covid ward, Bed No. 4 Impression/Diagnosis:Covid 19____________________

Dosage,
Name of Route,
Mechanism of Action Indication Adverse Reactions Special Precautions Nursing Responsibilities
Drug Frequency
and Timing
Generic: Dosage: Umifenovir is considered both a • prophylaxis and CNS: psychiatric • Mainly metabolized • Observe 14 rights of
direct-acting antiviral (DAA) due treatment of symptoms (depression, by the liver, it should drug administration.
Umifenovir 200 mg to direct virucidal effects and a acute confusion, etc) be used with caution • Inform the client that
influenza and other
host-targeting agent (HTA) due respiratory viral in patients with liver side effects such as
to effects on one or multiple Hepatic: Jaundice dysfunction or dizziness, nausea,
Route: infections.
stages of viral life cycle, and its • prophylactic agent Integumentary underlying hepatic diarrhea, vomiting,
Brand: Oral broad-spectrum antiviral activity for the prevention system: disease Ghasemiyeh, dermatitis, and pruritus
is thought to be due to this dual of COVID-19 caused et al. (2020). can be expected.
Arbidol activity (Drugbank, 2021). by SARS-CoV-2 Stevens–Johnson • Monitor the client for any
infections. syndrome/toxic • Studies have shown side effects or adverse
Frequency: Its antiviral mechanism is mainly epidermal necrolysis,
(Drugbank, 2021) this medication to effects. Inform the
as follows: angioedema allergic or have numerous drug- healthcare provider if
t.i.d.
a) inhibition of the membrane an idiosyncratic drug interactions any adverse effects
fusion between viral particles cutaneous drug (Drugbank, 2021) occur.
and plasma membranes, reactions • To manage pruritus,
Timing: apply a topical
b) regulation of the immune (Türsen et al., 2020)
Not indicated response by producing medication as prescribed
Classification interferons and activating Contraindications Side Effects by the physician, such as
macrophages, Calamine lotion.
Functional: (Ghaderkhani o Hypersensitivity • dizziness • Note the other
et al., 2021) c) modulation of the expression o children under two • nausea medications the client is
Antivirals of inflammatory cytokines such years of age • diarrhea currently taking and
Chemical: as interleukin-6, interleukin-8, o pregnant and • Vomiting inform the healthcare
and TNF α. lactating women • Dermatitis provider because studies
have shown this
 West Visayas State University
COLLEGE OF NURSING
Luna St., La Paz, Iloilo City 5000
Iloilo, Philippines
* Trunkline: (063) (033) 320-0870 loc 1313 * Telefax No.: (033) 320-0879 Acc. No.:
* Website: www.wvsu.edu.ph * Email Address: con@wvsu.edu.ph
PHI-18939-2-QM

DRUG STUDY

C22H25BrN2O3S Due to its ability to interact with o abnormal liver or • Pruritus medication to have
both viral proteins and lipids, it renal function numerous drug-drug
may interfere with later stages (Ghaderkhani et al., interactions.
of the viral life cycle. Some virus 2021) • Assist the patient to take
families replicate in a subcellular the medicine exactly as
compartment called the prescribed by the doctor.
membranous web, which • Ensure that the
requires lipid-protein treatment course is
interactions that may be completed.
hindered by umifenovir. • Store medication in a
(Drugbank, 2021) cool, dry place, away
from direct heat and
light.

References:

Drugbank. (2021). Umifenovir. https://go.drugbank.com/drugs/DB13609

Ghaderkhani, S., Salami Khaneshan, A., & Salami, A., et al. (2021). Efficacy and Safety of Arbidol in Treatment of Patients with COVID-19 Infection: A Randomized Clinical Trial.
[https://doi.org/10.21203/rs.3.rs-91430/v3
Ghasemiyehh, P., Borhani-Haghighi, A., Karimzadeh, I., Mohammadi-Samani, S., Vazin, A., Safari, A., and Qureshi, A. (2020). Major Neurologic Adverse Drug Reactions, Potential
Drug–Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review. Therapeutics and clinical risk management, 16,
595–605. https://doi.org/10.2147/TCRM.S259152
Huang, D., Yu, H., Wang, T., Yang, H., Yao, R., & Liang, Z. (2021). Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-
analysis. Journal of medical virology, 93(1), 481–490. https://doi.org/10.1002/jmv.26256
Türsen, U., Türsen, B., & Lotti, T. (2020). Cutaneous sıde-effects of the potential COVID-19 drugs. Dermatologic Therapy. https://doi.org/10.1111/dth.13476

Student’s Name: Heredia, Ignacio, Inosanto, Jadoc, Javellona, Jover, Lamaton, Lanado & Lao
Clinical Instructor: Prof. Virginia F. Federiso RN, MAN